Table 1 Characteristics of the studies included in this meta-analysis
From: Efficacy of mesenchymal stem cells in animal models of lupus nephritis: a meta-analysis
Author, year | n | Type of animal | MSC type | Number of MSC | Route of delivery | Endpoints |
|---|---|---|---|---|---|---|
Sun 2009 [10] | 12 | MRL/lpr mice | BM-MSC | 0.1 × 106 cells per 10 g body weight | Intravenous | ds-DNA, albumin, proteinuria, IgM, Foxp3, IL-6, IL-17 |
Gu 2010 [11] | 8 | MRL/lpr mice | UC-MSC | 1 × 106; multi-treatment (at the 18th, 19th, and 20th weeks of age) | Intravenous | Proteinuria, BUN, Scr, ds-DNA, MCP-1, Foxp3 |
Chang 2011 [12] | 8 | NZB/W F1 mice | UC-MSC | 1 × 106 | Intravenous | Proteinuria, Scr, ds-DNA, IFN-γ, TNF-α, IL-2, IL-6, IL-12, IL-4, IL-10, renal sclerosis score |
Choi 2012 [13] | 26 | NZB/W F1 mice | AD-MSC | 1.4 × 107 | Intravenous | Proteinuria, BUN, Scr, ds-DNA |
Ji 2012 [14] | 10 | MRL/lpr mice | BM-MSC | 0.2 × 106 cells per 10 g body | Intravenous | ds-DNA, ANA, proteinuria |
Ma 2013 [15] | 9 | MRL/lpr mice | BM-MSC | 1 × 106 | Intravenous | Proteinuria, ds-DNA |
Li 2013 [16] | 7 | 129X1/svj mice | BM-MSC | 1 × 106 | Intravenous | Proteinuria, BUN, renal sclerosis score, MCP-1 |
Liu 2014 [17] | 4 | MRL/lpr mice | BM-MSC | 1 × 106 | Intravenous | Proteinuria, Scr |
Che 2014 [18] | 10 | MRL/lpr mice | BM-MSC | 0.1 × 106 cells per 10 g body | Intravenous | ds-DNA, ANA, IL-10, TGF-β |
Park 2015 [19] | 6 | Roquinsan/san mice | AD-MSC | 1 × 106 for 5 weeks | Intravenous | IgM, ds-DNA, Th1, Th17, Treg |
Choi 2015 [20] | 15 | MRL/lpr mice | AD-MSC | 1 × 106 | Intravenous | Proteinuria, MCP-1, TNF-α, IL-2, IL-4, IL-6, IL-10, IL-12, IL-15, IL-17 |
Jang 2016 [21] | 8 | NZB/W mice | BM-MSC | 1 × 106 for 5 weeks | Intravenous | ds-DNA, proteinuria |
Choi 2016 [22] | 15 | NZB/W mice | AD-MSC | 5 × 105 for 27 times | Intravenous | BUN, ds-DNA |
Yuan 2016 [23] | 16 | MRL/Lpr mice | human early embryonic MSC (hMSC) | 1 × 106 | Intravenous | ds-DNA, albumin, proteinuria, Scr, BUN, IL-17, IL-10, TGF-β |
He 2016 [24] | 6 | B6.MRL/lpr mice | AD-MSC | 1 × 106 | Intravenous | ds-DNA, proteinuria, IL-17, IL-6, INF-γ, TGF-β, TNF-α |
Choi 2016 [25] | 20 | C3.MRL-Faslpr/J mice | AD-MSC | 1 × 106 | Intravenous | ds-DNA, Scr, BUN, Treg, Th1 |
Zhang 2017 [26] | 5 | B6.MRL-Faslpr mice | UC-MSC | 1 × 106 | Intravenous | ds-DNA, Th17, renal sclerosis score |
Lee 2017 [27] | 5 | MRL-Faslpr mice | BM-MSC | 4 × 106 | Intravenous | ds-DNA, proteinuria |
Yang 2018 [28] | 6 | MRL/lpr mice | BM-MSC | 2 × 106 | Intravenous | Renal sclerosis score, proteinuria, ds-DNA |
Tani 2017 [29] | 5 | NZB/W F1 mice | BM-MSC | 1 × 106 | Intravenous | Proteinuria, ds-DNA, renal sclerosis score |
Mai 2018 [30] | 4 | MRL/lpr mice | UC-MSC | 1 × 106 | Intravenous | ds-DNA, proteinuria, IFN-γ, TGF-β, MCP-1, IgM, IL-2, IL-10 |
Ma 2018 [31] | 8 | MRL/lpr mice | UC-MSC | 1 × 106 | Intravenous | Scr, proteinuria, IgM, C3, |
Zhang 2019 [32] | 3 | B6.MRL-Faslpr mice | UC-MSC | 1 × 106 | Intravenous | Renal sclerosis score, proteinuria, ds-DNA |
Lee JH 2018 [33] | 6 | MRL-Faslpr mice | BM-MSC | 4 × 104 | Intravenous | ds-DNA, proteinuria |
Huang 2018 [34] | 12 | MRL-Faslpr mice | UC-MSC | 1 × 106 | Intravenous | Renal sclerosis score, ds-DNA, proteinuria |
Liu 2019 [35] | 10 | B6.MRL-Faslpr mice | placenta-derived mesenchymal stem cells (pMSC) | 1 × 106 | Intravenous | ds-DNA, proteinuria, TNF-α |
Tang 2019 [36] | 10 | B6.MRL-Faslpr mice | UC-MSC | 2 × 105 per 10 g body | Intravenous | ds-DNA, proteinuria, ANA, IgG, IgM, renal sclerosis score, IL-6, IL-17, IL-10, MCP-1 |